Carboxypeptidase G2 for Methotrexate Intoxication
Author Information
Author(s): Buchen S, Ngampolo D, Melton R G, Hasan C, Zoubek A, Henze G, Bode U, Fleischhack G
Primary Institution: Children's Medical Hospital, University of Bonn, Bonn, Germany
Hypothesis
Can carboxypeptidase G2 effectively eliminate methotrexate in patients with renal failure?
Conclusion
Carboxypeptidase G2 is a safe and effective method for eliminating methotrexate in patients with delayed excretion due to renal failure.
Supporting Evidence
- CPDG2 resulted in a rapid 97% reduction of the MTX serum level.
- Patients experienced no toxicity related to CPDG2.
- Half of the patients had documented toxicity related to MTX.
- Four patients died due to severe myelosuppression and septic complications despite CPDG2 administration.
Takeaway
This study shows that a special medicine called carboxypeptidase G2 can help get rid of a harmful drug called methotrexate from sick kids' bodies when their kidneys aren't working well.
Methodology
A prospective, open, nonrandomised, multicentre trial administering CPDG2 to patients with high methotrexate levels and renal failure.
Potential Biases
Potential bias due to nonrandomized design and reliance on self-reported data.
Limitations
Data was incomplete for 17 patients, and the study was not randomized.
Participant Demographics
Patients aged 0.9 to 71.8 years, median age 15.4 years, with various cancers including acute lymphoblastic leukaemia and osteosarcoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website